Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.

By Sven Hoffmeyer, O. Burk, O. Richter, H. Arnold, J. Brockmöller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum and 1 more. Proceedings of the National Academy of Sciences of the United States of America, 2000

2,595 citations recorded by the source corpus.

Subfields: Oncology, Pediatrics, Perinatology and Child Health, Surgery

View Paper: https://www.semanticscholar.org/paper/22391fa58362b6bc2276abc7c5093c73c1b38fa5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pediatrics, Perinatology and Child Health

In Surgery

Citations in the corpus

Pharmacogenomics and individualized drug therapy. (2006, background): “A total of 28 SNPs have now been identified; those in exons 21 (G2677T) and 26 (C3435T) are of particular interest because they affect expression or function (77, 78).”
Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation (2010, background): “…mice, clinical pharmacokinetic analysis of the I1145I ABCB1 (MDR1) variant has yielded conflicting findings with regard to the disposition of a single oral digoxin dose (Table 19) (Hoffmeyer et al., 2000; Sakaeda et al., 2001; Morita et al., 2003b; Verstuyft et al., 2003; Chowbay et al., 2005).”
Mechanisms of cancer drug resistance. (2002, background): “Recent data also suggest that a noncoding polymorphism in the P-gp gene is closely linked to levels of expression of P-gp in the GI tract, which results in alterations in absorption of commonly used drugs such as digoxin (55).”
P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. (2005, background): “Several Pgp single nucleotide polymorphisms, such as the exon 26 3435T allele, have been described that decrease Pgp expression and result in functional differences in oral absorption and disposition of drugs (22).”
P-glycoprotein: from genomics to mechanism (2003, background): “A methodical screening for polymorphisms of the entire MDR1 gene, performed by Hoffmeyer et al. (2000) on a healthy Caucasian population, revealed 15 different SNPs in exons and introns.”
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus (2003, neutral): “5 (40-370) 210 (90-380) 12 mo 145 (80-430) 140 (20-320) 125 (75-290) Cyclosporine C0/dose (ng/mL per mg/kg) 3 mo 45.”
Frequency of single nucleotide polymorphisms in the P‐glycoprotein drug transporter MDR1 gene in white subjects (2001, background): “The frequency distribution of SNPs identified in those subjects was subsequently investigated in 85 to 188 subjects”